Arteriovenous Fistula Cannulation Practices and Dialysis Adequacy
Launched by ISTANBUL DEMIROGLU BILIM UNIVERSITY · Feb 12, 2020
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
As hemodialysis prescriptions are usually three times weekly (4 to 8 h), a fistula or graft for hemodialysis will be punctured twice each dialysis treatment or at least 312 times per year. To allow healing of the tissues damaged during each cannulation, optimal cannulation practice is required by rotation of the needle insertion sites each dialysis treatment. Vascular access (VA) has been justly described as both the lifeline and the Achilles' heel of hemodialysis therapy, making blood purification itself possible while simultaneously often constituting a limiting factor in treatment adequacy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 and older years of age
- • Have arteriovenous fistula
- • Being on hemodialysis therapy for 4 hours a day on 3 days per week for at least 6 months
- • Volunteering to participate in the study
- • Have not communication problem
- Exclusion Criteria:
- • Younger than 18 years old
- • Not volunteering to participate in the study
- • Have communication problem
- • Being on shorter hemodialysis therapy for 4 hours a day on 3 days per week for at least 6 months
About Istanbul Demiroglu Bilim University
Istanbul Demiroglu Bilim University is a leading institution dedicated to advancing medical research and education in Turkey. Committed to innovative healthcare solutions, the university sponsors clinical trials that aim to enhance patient outcomes and contribute to the scientific community. With a focus on interdisciplinary collaboration and state-of-the-art facilities, Istanbul Demiroglu Bilim University fosters an environment conducive to the development of novel therapeutic approaches and the rigorous evaluation of medical interventions. Through its clinical research initiatives, the university strives to bridge the gap between laboratory discoveries and clinical applications, ultimately improving the quality of care for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, Sisli, Turkey
Patients applied
Trial Officials
Nurten Ozen, Asst. Prof.
Principal Investigator
Istanbul Demiroglu Bilim University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials